Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O00443

UPID:
P3C2A_HUMAN

ALTERNATIVE NAMES:
Phosphoinositide 3-kinase-C2-alpha

ALTERNATIVE UPACC:
O00443; B0LPH2; B4E2G4; Q14CQ9

BACKGROUND:
The enzyme Phosphoinositide 3-kinase-C2-alpha, integral for generating key lipid signaling molecules, is involved in numerous cellular functions such as endocytosis, insulin-mediated glucose transport, and cell signaling pathways. Its activity is essential for maintaining normal cellular and physiological processes.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Oculoskeletodental syndrome, targeting Phosphoinositide 3-kinase-C2-alpha offers a promising avenue for therapeutic intervention. Exploring its mechanisms further could lead to novel treatments for this syndrome and potentially other related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.